XML 44 R13.htm IDEA: XBRL DOCUMENT
v3.22.1

Accrued Expenses and Other Current Liabilities | 12 Months Ended
--- | ---
Dec. 31, 2021
Other Liabilities Disclosure [Abstract] |
Accrued Expenses and Other Current Liabilities | Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following:
| December 31,
| 2021 |  | 2020
Compensation and benefits | $ | 436,990 |  |  | $ | — |
Clinical trial expenses | 339,072 |  |  | 126,173 |
Manufacturing development expenses | — |  |  | 560,000 |
Professional fees | 345,530 |  |  | — |
Other accrued expenses and other current liabilities | 85,529 |  |  | 269,816 |
Total accrued expenses and other current liabilities | $ | 1,207,121 |  |  | $ | 955,989 |

X
- Definition The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + References No definition available. + Details
Name: | us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OtherLiabilitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration